Limmatech Biologics Ag
Clinical trials sponsored by Limmatech Biologics Ag, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a vaccine stop Antibiotic-Resistant gonorrhea? Results expected Apr 2027 (estimated)
- New vaccine could stop recurring yeast infections in their tracks Results expected Apr 2027 (estimated)
-
New shigella vaccine shows promise for infants in phase 2 trial
Vaccine CompletedThis study tested a new vaccine called Shigella4V2 to protect infants against shigellosis, a severe diarrheal disease. Researchers gave the vaccine to 110 healthy 9-month-old babies to check its safety and how well it triggers an immune response. The goal is to find the best dose…
Phase 2 • Sponsor: LimmaTech Biologics AG • Aim: Vaccine
Last updated Aug 09, 2026 00:00 UTC
-
New staph vaccine shows promise in early human trial
Vaccine CompletedThis early-stage study tested a new vaccine called LTB-SA7 designed to protect against infections caused by Staphylococcus aureus bacteria. 129 healthy adults received either the vaccine or a placebo to check for safety and to see if the vaccine triggers an immune response. The s…
Phase 1 • Sponsor: LimmaTech Biologics AG • Aim: Vaccine
Last updated Aug 05, 2026 00:00 UTC
-
New vaccine aims to protect infants from deadly diarrhea
Vaccine CompletedThis study tests a new vaccine called Shigella4V, designed to protect against shigellosis, a severe diarrheal disease. Researchers are giving the vaccine to healthy adults, children, and 9-month-old infants to check its safety and whether it triggers a strong immune response. Dif…
Phase 1/2 • Sponsor: LimmaTech Biologics AG • Aim: Vaccine
Last updated Jun 27, 2026 14:03 UTC